Type 2 diabetes: NICE to approve exenatide (Bydureon)

Type 2 diabetes: NICE to approve exenatide (Bydureon): "Type 2 diabetes: NICE to approve exenatide
In draft guidance long-acting exenatide (Bydureon) is recommended for triple therapy for some patients with type 2 diabetes

18th October 2011 - In preliminary recommendations the National Institute for Health and Clinical Excellence (NICE) says that a long-acting injection of exenatide (also known as Bydureon) is suitable in triple therapy treatment for some people with type 2 diabetes.

Diabetes UK says exenatide mimics a hormone found in the Gila lizard and is given via once weekly injections. There is also a twice-daily short-acting version of exenatide (called Byetta) but that preparation is not the subject of this NICE draft guidance.
"

'via Blog this'